AMNEAL PHARMACEUTICALS, INC. Current Income Tax Expense (Benefit)
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Current Income Tax Expense (Benefit) of $11.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2025 was $11.28M, a 40.22% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2024 was $18.86M, a 123.18% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2023 was $8.45M, a 26.87% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2022 was $6.66M, a 40.50% decline from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $11.28M 10-K · filed 2026-02-27 |
| 2024-12-31 | $18.86M 10-K · filed 2026-02-27 |
| 2023-12-31 | $8.45M 10-K · filed 2026-02-27 |
| 2022-12-31 | $6.66M 10-K · filed 2025-02-28 |
| 2021-12-31 | $11.20M 10-K · filed 2024-03-14 |
| 2020-12-31 | -$104.36M 10-K · filed 2023-03-03 |
| 2019-12-31 | $11.62M 10-K · filed 2022-03-01 |
| 2018-12-31 | $8.02M 10-K · filed 2021-03-01 |
| 2017-12-31 | $1.26M 10-K · filed 2020-03-02 |
| 2016-12-31 | $5.27M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |